DETAILS

Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID	DDPD01015
Drug Name	Sulfamethoxazole
Molecular Weight	253.278
Molecular Formula	C10H11N3O3S
CAS Number	723-46-6
SMILES	CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
External Links
	DRUGBANK	DB01015
	PubChem Compound	5329

Experimental Physicochemical Property

Property Name	Property Value	Unit	Raw Value	Raw Unit	Reference
Log P	0.89	-	0.89	-	HANSCH,C ET AL. (1995)
Melting Point	167.0	℃	167	℃	PhysProp
Water Solubility	610.0	mg/L	610	mg/L	YALKOWSKY,SH & DANNENFELSER,RM 1992)
Log S	-2.62	-	-2.62	-	ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Factor	Reference
Bioavailability	88.0	%	86-90	%	PO, oral;		DRUGBANK
Bioavailability	100.0	%	~100	%	PO, oral;		The Pharmacological Basis of Therapeutics
C Max	62700.0	ng/ml	57.4-68	ug/ml	PO, oral;		DRUGBANK
C Max	37100.0	ng/ml	37.1	mcg/ml	Oral single dose; adults; normal,healthy;		The Pharmacological Basis of Therapeutics
T Max	2.5	h	1-4	h	PO, oral;		DRUGBANK
T Max	4.0	h	4.0	h	Oral single dose; adults; normal,healthy;		The Pharmacological Basis of Therapeutics
Clearance	0.0186	L/h/kg	0.31±0.07	ml/min/kg	normal,healthy; adults;	RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis ↑ ;	The Pharmacological Basis of Therapeutics
Clearance	0.0216	L/h/kg	0.36	ml/min/kg	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Volume of Distribution	13.0	L	13.0	L	PO, oral;		DRUGBANK
Volume of Distribution	0.26	L/kg	0.26±0.04	L/kg	normal,healthy; adults;	Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;	The Pharmacological Basis of Therapeutics
Volume of Distribution	0.30	L/kg	0.3	L/kg	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Half-life	10.0	h	10	h	elimination half-life;	RD, renal impairment, Renal disease，including uremia ↑ ;	DRUGBANK
Half-life	10.1	h	10.1±2.6	h		Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis ↓ ;normal BMI → ;	The Pharmacological Basis of Therapeutics
Half-life	9.8	h	9.8	h	intravenous injection, IV; human, homo sapiens;		Human Intravenous Pharmacokinetic Dataset
Toxicity LD50	2300.0	mg/kg	2300.0	mg/kg	PO, oral; mouse;		DRUGBANK
Toxicity LD50	6200.0	mg/kg	6200.0	mg/kg	PO, oral; Rattus, Rat;		DRUGBANK
Eliminate Route	84.5	%	~84.5	%	Urinary excretion; Oral single dose;		DRUGBANK
Eliminate Route	14.0	%	14±2	%	Urinary excretion; Unchanged drug;		The Pharmacological Basis of Therapeutics
Protein Binding	70.0	%	~70	%	plasma proteins;		DRUGBANK
Protein Binding	53.0	%	53±5	%		Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;hypoalbuminemia Alb ↓ ;Cystic fibrosis → ;	The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1